Search results for "Phase IV Trial"

showing 3 items of 3 documents

Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smok…

2007

Aims: To assess the role of smoking on treatment outcome in quitting alcoholics on the background of the priming or coping hypothesis (Rohsenow et al. , [1997][1]). Methods: Data sets of placebo treated patients of the German phase III trial of naltrexone (Gastpar et al. , [2002][2]) and of acamprosate treated patients of a German phase IV trial Soyka et al. , [2002][3]) were reanalyzed. Differences between smoking and non-smoking alcoholics were evaluated using χ2-, t - or ANOVA-tests, relapse rates using survival techniques with Cox regression. Results: Smoking alcoholics differed significantly from non-smoking alcoholics regarding sociodemographic variables (e.g. more males, more often l…

AdultMalemedicine.medical_specialtyCoping (psychology)TaurineAcamprosateNarcotic AntagonistsTemperanceComorbidityPlaceboPhase IV TrialSeverity of Illness IndexNaltrexonePharmacotherapySex FactorsRecurrenceInternal medicinemedicineOdds RatioHumansPsychiatryProportional Hazards Modelsbusiness.industryProportional hazards modelSmokingGeneral MedicineMiddle AgedNaltrexoneClinical trialAlcoholismAcamprosateTreatment OutcomeMultivariate AnalysisFemalebusinessmedicine.drugAlcohol DeterrentsAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and…

2014

e20724 Background: Anti-EGFR empowered chemotherapeutic regimens resulted in increased overall survival (OS) and response rates (RR). Anti-EGFR induced skin rash occurs in ~ 70% patients, and ~18% ...

OncologySkin careCancer Researchmedicine.medical_specialtyCetuximabColorectal cancerbusiness.industrymedicine.diseaseRashPhase IV TrialSurgeryFirst line treatmentOncologyInternal medicinemedicineFOLFIRIOverall survivalmedicine.symptombusinessmedicine.drugJournal of Clinical Oncology
researchProduct

189TiP Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutat…

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industryAfatinibPhase IV TrialFirst line treatmentOncologyEgfr mutationInternal medicinemedicineOsimertinibIn patientbusinessmedicine.drugJournal of Thoracic Oncology
researchProduct